Their innovation engine identifies multiple rare diseases that share a common biology and discovers novel therapeutics that can treat these diseases with a single therapy. Star consists of a family of companies, each focusing on a specific area of novel biology and developing first-in-class antibody therapeutics. Electra Therapeutics, the first company within their portfolio, is developing therapies that target signal regulatory proteins (SIRP) for the treatment of immunological diseases and cancer.